These cells demonstrated effectiveness in eliminating double-positive (CD19+CD20+) and single-positive (CD19+ and/or CD20+) tumor cells, presenting a novel advancement for the clinical application of dual-target CAR-NK cell therapy in ALL treatment. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.